^
Association details:
| Biomarker: | ALK G1269A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Excerpt:
The activity of ceritinib against nine additional ALK mutations conferring resistance to crizotinib was tested in Ba/F3 cells. Ceritinib potently inhibited the growth of those cells expressing the most common mutations, L1196M, G1269A and also S1206Y and I1171T, but not those with C1156Y, G1202R, 1151Tins, L1152R and F1174C mutations...
DOI:
10.2147/DDDT.S113500
Source:
Title:
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
Excerpt:
These data demonstrate that ceritinib is active against cancers derived from patients with acquired resistance to crizotinib and is more potent than crizotinib against ALK-rearranged cancers harboring the L1196M and G1269A resistance mutations.
DOI:
10.1158/2159-8290.CD-13-0846
